CAAP Peptide Panel for Sepsis Diagnosis via LC/MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic markers for sepsis lack specificity and sensitivity, failing to reliably differentiate infectious-induced from non-infectious-induced systemic inflammation, which is crucial for early diagnosis and risk stratification, particularly in polytraumatized patients without underlying infection.
Innovation Solution
A mass-spectrometry based method for detecting specific peptides formed by protease-mediated proteolysis, using a panel of C-terminal peptides of alpha-1-antitrypsin (CAAPs) as clinical diagnostic markers, enabling the differentiation of infectious-induced from non-infectious-induced systemic inflammation through multiplex multiple reaction monitoring (MRM) scanning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic markers (CRP, PCT, interleukins) are used for sepsis diagnosis, then the diagnosis can be performed, but the sensitivity and specificity are insufficient to reliably differentiate infectious-induced from non-infectious-induced systemic inflammation
Solution Approach 1:
The patent segments the diagnostic approach by identifying and measuring specific proteolytic cleavage products (CAAPs) of alpha-1-antitrypsin rather than using whole protein markers. This segmentation allows detection of specific inflammatory pathways activated in sepsis, improving the ability to differentiate infectious from non-infectious inflammation with higher sensitivity and specificity.
Solution Approach 2:
The patent uses CAAPs as intermediary markers that reflect protease activity in the inflammatory response. These cleavage products serve as mediators between the infectious stimulus and the diagnostic measurement, providing more specific information about the nature of inflammation compared to traditional markers like CRP or PCT.
2Loss of time
If traditional biomarker panels are used, then diagnosis can be performed, but early diagnosis and risk stratification are compromised due to lack of specificity
Solution Approach 1:
The patent enables preliminary action by detecting CAAPs at very early stages of sepsis development, before traditional markers show significant changes. The proteolytic cleavage of alpha-1-antitrypsin occurs early in the inflammatory cascade, allowing for earlier diagnosis and intervention while maintaining high diagnostic specificity through the use of specific peptide fragment measurement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides sensitive and specific detection of sepsis and its early stages by correlating CAAP levels with infectious-induced systemic inflammation, improving diagnostic accuracy and enabling timely clinical intervention.
Implementation Method 1
detecting specific peptides formed by protease-mediated proteolysis
Implementation Method 2
A mass-spectrometry based method for detecting specific peptides
Implementation Method 3
multiplex multiple reaction monitoring (MRM) scanning
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to a method for quantitatively measuring a concentration of a peptide panel in a biological matrix by mass spectrometry detection, wherein multiplex multiple reaction monitoring (MRM) scanning is applied.